
Anna Mary Bofin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6277038/publications.pdf Version: 2024-02-01



ANNA MARY ROFIN

#	Article	IF	CITATIONS
1	<i>FGFR1</i> copy number in breast cancer: associations with proliferation, histopathological grade and molecular subtypes. Journal of Clinical Pathology, 2022, 75, 459-464.	1.0	4
2	CCND1 Amplification in Breast Cancer -associations With Proliferation, Histopathological Grade, Molecular Subtype and Prognosis. Journal of Mammary Gland Biology and Neoplasia, 2022, 27, 67-77.	1.0	17
3	Visual and digital assessment of Ki-67 in breast cancer tissue - a comparison of methods. Diagnostic Pathology, 2022, 17, 45.	0.9	4
4	ZNF703 gene copy number and protein expression in breast cancer; associations with proliferation, prognosis and luminal subtypes. Breast Cancer Research and Treatment, 2021, 186, 65-77.	1.1	5
5	DTX3 copy number increase in breast cancer: a study of associations to molecular subtype, proliferation and prognosis. Breast Cancer Research and Treatment, 2021, 187, 57-67.	1.1	6
6	The association of women's birth size with risk of molecular breast cancer subtypes: a cohort study. BMC Cancer, 2021, 21, 299.	1.1	3
7	Reproducible Lipid Alterations in Patient-Derived Breast Cancer Xenograft FFPE Tissue Identified with MALDI MSI for Pre-Clinical and Clinical Application. Metabolites, 2021, 11, 577.	1.3	9
8	Stromal Collagen Content in Breast Tumors Correlates With In Vivo Diffusionâ€Weighted Imaging: A Comparison of Multi <i>b</i> â€Value DWI With Histologic Specimen From Benign and Malignant Breast Lesions. Journal of Magnetic Resonance Imaging, 2020, 51, 1868-1878.	1.9	16
9	The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers. Scientific Reports, 2020, 10, 1277.	1.6	22
10	MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes. Breast Cancer Research and Treatment, 2020, 180, 73-86.	1.1	13
11	Microvessel density in breast cancer: the impact of field area on prognostic informativeness. Journal of Clinical Pathology, 2019, 72, 304-310.	1.0	8
12	Nephronectin is Correlated with Poor Prognosis in Breast Cancer and Promotes Metastasis via its Integrin-Binding Motifs. Neoplasia, 2018, 20, 387-400.	2.3	26
13	Characterization of FGD5 Expression in Primary Breast Cancers and Lymph Node Metastases. Journal of Histochemistry and Cytochemistry, 2018, 66, 787-799.	1.3	9
14	The prognostic value of androgen receptors in breast cancer subtypes. Breast Cancer Research and Treatment, 2018, 172, 283-296.	1.1	38
15	FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis. Breast Cancer Research and Treatment, 2017, 162, 243-253.	1.1	12
16	Quantifying tumour vascularity in non-luminal breast cancers. Journal of Clinical Pathology, 2017, 70, 766-774.	1.0	9
17	Basal markers and prognosis in luminal breast cancer. Breast Cancer Research and Treatment, 2017, 163, 207-217.	1.1	6
18	SFRP4 gene expression is increased in aggressive prostate cancer. Scientific Reports, 2017, 7, 14276.	1.6	23

Anna Mary Bofin

#	Article	IF	CITATIONS
19	Prevalence of human papillomavirus infection among women in rural Nepal. Acta Obstetricia Et Gynecologica Scandinavica, 2017, 96, 29-38.	1.3	11
20	A novel non-canonical Wnt signature for prostate cancer aggressiveness. Oncotarget, 2017, 8, 9572-9586.	0.8	59
21	<i>HER2</i> gene copy number and breast cancerâ€specific survival. Histopathology, 2016, 69, 871-879.	1.6	13
22	Molecular Subtypes of Breast Cancer: Long-term Incidence Trends and Prognostic Differences. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1625-1634.	1.1	30
23	Alterations in collagen fibre patterns in breast cancer. A premise for tumour invasiveness?. Apmis, 2015, 123, 1-8.	0.9	51
24	Microvascular proliferation in luminal A and basal-like breast cancer subtypes. Journal of Clinical Pathology, 2015, 68, 891-897.	1.0	23
25	Papanicolaou smear history in women with low-grade cytology before cervical cancer diagnosis. Cancer, 2007, 111, 210-216.	2.0	16
26	Cytological criteria for the diagnosis of intraductal hyperplasia, ductal carcinoma in situ, and invasive carcinoma of the breast. Diagnostic Cytopathology, 2004, 31, 207-215.	0.5	33
27	Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. American Journal of Clinical Pathology, 2004, 122, 110-9.	0.4	35
28	Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer. Oncotarget, 0, 7, 42071-42085.	0.8	28